Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma

Figure 4

Response to chemotherapy in metastatic myxoid liposarcoma. Computed tomography (a–c) before and (d–f) after 3 cycles of trabectedin showing progressive disease. Partial response was obtained 5 months after treatment with eribulin (g–i). The tumors were under control for another 10 months (j–l).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)